secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001213900-26-039529
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies completes $5.25M registered direct offering, expects $4M non-dilutive funds from UK subsidiary
--------------------------------------------------------------------------------

- Gross proceeds $5.25M; net proceeds ~$4.7M from offering of 2.5M shares (or pre-funded warrants) and 3.8M common warrants at $1.40/share.
- Expects ~$2M VAT refunds from UK sub. in Q2 2026 and ~$2M R&D tax credits in H2 2026.
- Combined funding expected to extend cash runway into 2027.
- Targets OST-HER2 regulatory approvals (US FDA, UK MHRA, EU EMA) in H2 2026.
- 90-day lockup on further equity issuance; Ceros received 7% fee and warrants at $1.54.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390026039529/0001213900-26-039529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390026039529/ea0284488-8k_ostherapies.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-039529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer